{
    "clinical_study": {
        "@rank": "68691", 
        "arm_group": {
            "arm_group_label": "ACE 536", 
            "arm_group_type": "Experimental", 
            "description": "ACE-536 - 1 of 7 possible dose levels."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of ACE-536 in patients with\n      beta-thalassemia."
        }, 
        "brief_title": "Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Beta-thalassemia.", 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will evaluate the safety and tolerability of ACE-536 in beta-thalassemia patients\n      with anemia and the ability of ACE-536 to generate an erythroid response in these patients.\n      An erythroid response in this study is defined as: 1) a hemoglobin increase of \u2265 1.5 g/dL\n      from baseline for \u2265 14 days (in the absence of red blood cell [RBC] transfusions) in\n      non-transfusion dependent patients, or 2) \u2265 20% reduction in RBC transfusion burden compared\n      to pretreatment in transfusion dependent patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Documented diagnosis of beta-thalassemia intermedia, with anemia requiring at least\n             1, but no more than 6 transfusion events in the last year, with no transfusion events\n             for 56 days prior to Cycle 1 Day 1.\n\n          -  Prior splenectomy or spleen size < 18 cm in the longest diameter by abdominal\n             ultrasound.\n\n          -  Mean hemoglobin concentration < 10.0 g/dL of 2 measurements (one performed within one\n             day prior to Cycle 1 Day 1 and the other performed 7-28 days prior, not influenced by\n             RBC transfusion within 7 days of measurement).\n\n          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x upper limit\n             of normal (ULN).\n\n          -  Serum creatinine \u2264 1.5 x ULN.\n\n          -  Females of child bearing potential (defined as sexually mature women who have not\n             undergone hysterectomy or bilateral oophorectomy, or are not naturally postmenopausal\n             \u2265 24 consecutive months) must have negative urine or blood pregnancy test prior to\n             enrollment and use adequate birth control methods (abstinence, oral contraceptives,\n             barrier method with spermicide, or surgical sterilization) during study\n             participation. Males must agree to use a latex condom during any sexual contact with\n             females of child-bearing potential while participating in the study and for 12 weeks\n             following the last dose of ACE 536, even if he has undergone a successful vasectomy.\n             Patients must be counseled concerning measures to be used to prevent pregnancy and\n             potential toxicities prior to the first dose of ACE-536.\n\n        Key Exclusion Criteria:\n\n          -  Any clinically significant pulmonary (including pulmonary hypertension),\n             cardiovascular, endocrine, neurologic, hepatic, gastrointestinal, infectious,\n             immunological (including clinically significant allo- or auto-immunization) or\n             genitourinary disease considered by the investigator as not adequately controlled\n             prior to Cycle 1 Day 1.\n\n          -  Folate deficiency.\n\n          -  Symptomatic splenomegaly.\n\n          -  Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B\n             (HBV) or active infectious hepatitis C (HCV).\n\n          -  Known history of thromboembolic events \u2265 grade 3 according to the National Cancer\n             Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0 (current\n             active minor version).\n\n          -  Ejection fraction < 50% by echocardiogram, MUGA or cardiac MRI.\n\n          -  Uncontrolled hypertension defined as systolic blood pressure (BP) \u2265 150 mm Hg or\n             diastolic BP \u2265 95 mm Hg.\n\n          -  Heart failure class 3 or higher (New York Heart Association, NYHA).\n\n          -  QTc > 450 msec on screening ECG.\n\n          -  Platelet count < 100 x109/L or > 1,000 x109/L.\n\n          -  Proteinuria \u2265 Grade 2.\n\n          -  Any active infection requiring parenteral antibiotic therapy within 28 days prior to\n             Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.\n\n          -  Treatment with another investigational drug or device, or approved therapy for\n             investigational use \u2264 28 days prior to Cycle 1 Day 1, or if the half-life of the\n             previous investigational product is known, within 5 times the half-life prior to\n             Cycle 1 Day 1, whichever is longer.\n\n          -  Transfusion event within 7 days prior to Cycle 1 Day 1.\n\n          -  Patients receiving or planning to receive hydroxyurea treatment. Patients must not\n             have had hydroxyurea within 56 days of Cycle 1 Day 1.\n\n          -  Splenectomy within 56 days prior to Cycle 1 Day 1.\n\n          -  Major surgery (except splenectomy) within 28 days prior to Cycle 1 Day 1. Patients\n             must have completely recovered from any previous surgery prior to Cycle 1 Day 1.\n\n          -  Iron chelation therapy initiated within 56 days prior to Cycle 1 Day 1.\n\n          -  Cytotoxic agents, systemic corticosteroids, immunosuppressants, or anticoagulant\n             therapy such as warfarin or heparin within 28 days prior to Cycle 1 Day 1\n             (prophylactic aspirin up to 100 mg/d is permitted)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749540", 
            "org_study_id": "A536-04"
        }, 
        "intervention": {
            "arm_group_label": "ACE 536", 
            "description": "Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.", 
            "intervention_name": "ACE-536", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turin", 
                        "country": "Italy"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey"
                    }, 
                    "name": "Acceleron Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Italy", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia", 
        "overall_contact": {
            "email": "clinicaltrials536@acceleronpharma.com", 
            "last_name": "Clinical Trials Manager", 
            "phone": "617-649-9200"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Agenzia Italiana del Farmaco (AIFA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients who have an erythroid response, defined as a 1) a hemoglobin increase of \u2265 1.5 g/dL from baseline for \u2265 14 days (in the absence of red blood cell [RBC] transfusions) in non-transfusion dependent patients, or 2) \u2265 20% reduction in RBC transfusion burden compared to pretreatment in transfusion dependent patients.", 
            "measure": "Proportion of patients who have an erythroid response.", 
            "safety_issue": "No", 
            "time_frame": "Assessed at approximately 24 weeks from patient screening."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "From treatment initiation to End-of-Study visit (approximately 24 weeks later)."
            }, 
            {
                "measure": "Change in hemoglobin level in non-transfusion dependent patients.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to approximately 24 weeks."
            }, 
            {
                "measure": "Changes in biomarkers of erythropoiesis, hemolysis, iron metabolism and bone metabolism.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to approximately 24 weeks."
            }, 
            {
                "measure": "ACE-536 pharmacokinetics.", 
                "safety_issue": "No", 
                "time_frame": "Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks."
            }
        ], 
        "source": "Acceleron Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acceleron Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}